Appleton Partners Inc. MA Has $205,000 Stock Position in Pfizer Inc. $PFE

Appleton Partners Inc. MA cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 25.8% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,468 shares of the biopharmaceutical company’s stock after selling 2,948 shares during the period. Appleton Partners Inc. MA’s holdings in Pfizer were worth $205,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in PFE. Brighton Jones LLC grew its position in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC lifted its stake in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares during the last quarter. Miracle Mile Advisors LLC grew its holdings in Pfizer by 6.2% during the first quarter. Miracle Mile Advisors LLC now owns 233,234 shares of the biopharmaceutical company’s stock worth $5,910,000 after purchasing an additional 13,534 shares during the period. Central Bank & Trust Co. increased its position in Pfizer by 18.8% during the first quarter. Central Bank & Trust Co. now owns 19,869 shares of the biopharmaceutical company’s stock worth $503,000 after buying an additional 3,140 shares during the last quarter. Finally, AHL Investment Management Inc. raised its stake in Pfizer by 7.4% in the first quarter. AHL Investment Management Inc. now owns 91,782 shares of the biopharmaceutical company’s stock valued at $2,326,000 after buying an additional 6,345 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent analyst reports. Morgan Stanley boosted their target price on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Saturday, September 27th. Bank of America increased their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday. UBS Group reaffirmed a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $28.41.

Pfizer Price Performance

NYSE:PFE opened at $26.45 on Tuesday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm’s 50-day simple moving average is $24.72 and its 200 day simple moving average is $24.12. The firm has a market cap of $150.38 billion, a price-to-earnings ratio of 14.07, a P/E/G ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the previous year, the firm posted $0.60 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.